Search
forLearn
5 / 801 resultslearn SDA 40
learn chodroitin sulfete
learn PTT-6®
learn nicotinamide
Research
5 / 1000+ results
research Successful induction of oral tolerance in Netherton syndrome
A girl with Netherton syndrome was able to eat wheat without allergies after a special treatment.
research Platelet-Rich Plasma for Degenerative Spine Disease: A Brief Overview
PRP shows promise for spinal pain but needs more guidelines before widespread use.
research Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
research The utility of the classification tools in National Institute of Health and Clinical Excellence’s Clinical Knowledge Summaries for primary care
Nearly half of the classification tools in the National Institute of Health and Clinical Excellence's Clinical Knowledge Summaries might not effectively guide management for general practitioners.
research Under Development JAK Inhibitors for Dermatologic Diseases
New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
Community Join
5 / 1000+ resultscommunity Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Koshine 826 (Pyrilutamide). Any results after 5 months since it's been released?
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
community Koshine comes under two names apparently
The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
community Upcoming Setipiprant clinical trials hint at systemic daily dosage
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.